Literature DB >> 1972704

Isolation and characterization of an adriamycin-resistant breast tumor cell line.

S L Schneider1, S A Fuqua, K V Speeg, A K Tandon, W L McGuire.   

Abstract

An adriamycin-resistant human breast tumor cell line MDA-A1R was generated by step-wise selection in increasing concentrations of drug from the parent cell line MDA-MB-231. MDA-A1R cells grow as loosely attached cell aggregates with a doubling time of 28-32 h; the MDA-MB-231 parent cell line grows as a standard monolayer culture with a 20-h doubling time. The MDA-A1R cell line is highly resistant to adriamycin compared to the parent cell line, and is cross-resistant to velban and colchicine suggestive of a multidrug resistance (MDR) phenotype. MDA-A1R cells exhibit reduced net adriamycin content as compared to the parent cell line. The MDR-associated P-glycoprotein gene is amplified approximately 10- to 30-fold in MDA-A1R cells. P-glycoprotein sequences are overexpressed in the resistant cells and are stable for up to 13 wk after drug removal. Moreover, MDA-A1R cells show the presence of very high levels of P-glycoprotein. MDA-A1R is thus an in vitro model system to study the mechanism of MDR in human breast cancer.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1972704     DOI: 10.1007/bf02624212

Source DB:  PubMed          Journal:  In Vitro Cell Dev Biol        ISSN: 0883-8364


  34 in total

1.  Mammalian multidrug resistance gene: complete cDNA sequence indicates strong homology to bacterial transport proteins.

Authors:  P Gros; J Croop; D Housman
Journal:  Cell       Date:  1986-11-07       Impact factor: 41.582

2.  Multiple drug-resistant human KB carcinoma cells independently selected for high-level resistance to colchicine, adriamycin, or vinblastine show changes in expression of specific proteins.

Authors:  D W Shen; C Cardarelli; J Hwang; M Cornwell; N Richert; S Ishii; I Pastan; M M Gottesman
Journal:  J Biol Chem       Date:  1986-06-15       Impact factor: 5.157

3.  A fluorometric assay for daunomycin and adriamycin in animal tissues.

Authors:  H S Schwartz
Journal:  Biochem Med       Date:  1973-06

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  P-glycoprotein expression in human breast cancer cells.

Authors:  S A Fuqua; I M Moretti-Rojas; S L Schneider; W L McGuire
Journal:  Cancer Res       Date:  1987-04-15       Impact factor: 12.701

6.  Immunological detection of Chinese hamster ovary cells expressing a multidrug resistance phenotype.

Authors:  B Lathan; D P Edwards; L G Dressler; D D Von Hoff; W L McGuire
Journal:  Cancer Res       Date:  1985-10       Impact factor: 12.701

Review 7.  Drug resistance in Chinese hamster lung and mouse tumor cells.

Authors:  J L Biedler; T D Chang; M B Meyers; R H Peterson; B A Spengler
Journal:  Cancer Treat Rep       Date:  1983-10

8.  Adriamycin resistance in HL60 cells and accompanying modification of a surface membrane protein contained in drug-sensitive cells.

Authors:  W Marsh; M S Center
Journal:  Cancer Res       Date:  1987-10-01       Impact factor: 12.701

9.  A comparison of intermittent vs. continuous and of adriamycin vs. methotrexate 5-drug chemotherapy for advanced breast cancer. A Cancer and Leukemia Group B study.

Authors:  D C Tormey; V E Weinberg; L A Leone; O J Glidewell; M Perloff; B J Kennedy; E Cortes; R T Silver; R B Weiss; J Aisner
Journal:  Am J Clin Oncol       Date:  1984-06       Impact factor: 2.339

10.  Active efflux of daunorubicin and adriamycin in sensitive and resistant sublines of P388 leukemia.

Authors:  M Inaba; H Kobayashi; Y Sakurai; R K Johnson
Journal:  Cancer Res       Date:  1979-06       Impact factor: 12.701

View more
  9 in total

1.  Monitoring the chemosensitizing effects of toremifene with flow cytometry in estrogen receptor negative multidrug resistant human breast cancer cells.

Authors:  W J Baker; V J Wiebe; S K Koester; V D Emshoff; J U Maenpaa; G T Wurz; M W DeGregorio
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

Review 2.  How can grafted breast cancer models be optimized?

Authors:  Séverine Mollard; Yoanne Mousseau; Yasser Baaj; Laurence Richard; Jeanne Cook-Moreau; Jacques Monteil; Benoît Funalot; Franck G Sturtz
Journal:  Cancer Biol Ther       Date:  2011-11-15       Impact factor: 4.742

3.  The effects of cyclosporin A, tamoxifen, and medroxyprogesterone acetate on the enhancement of adriamycin cytotoxicity in primary cultures of human breast epithelial cells.

Authors:  J A Claudio; J T Emerman
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

4.  Rhodamine-loaded poly(lactic-co-glycolic acid) nanoparticles for investigation of in vitro interactions with breast cancer cells.

Authors:  Tania Betancourt; Kunal Shah; Lisa Brannon-Peppas
Journal:  J Mater Sci Mater Med       Date:  2008-09-25       Impact factor: 3.896

5.  Differential expression of steroid receptors, hsp27, and pS2 in a series of drug resistant human breast tumor cell lines derived following exposure to antitumor drugs or to fractionated X-irradiation.

Authors:  R D Whelan; B T Hill
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

6.  Drug resistance as a dynamic process in a model for multistep gene amplification under various levels of selection stringency.

Authors:  L E Harnevo; Z Agur
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

7.  In vitro screening of crude extracts and pure metabolites obtained from marine invertebrates for the treatment of breast cancer.

Authors:  J Stingl; R J Andersen; J T Emerman
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

8.  Assessment of antineoplastic agents by MTT assay: partial underestimation of antiproliferative properties.

Authors:  S B Sobottka; M R Berger
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

9.  P-glycoprotein mediated resistance to 5'-nor-anhydro-vinblastine (Navelbine).

Authors:  D J Adams; V C Knick
Journal:  Invest New Drugs       Date:  1995       Impact factor: 3.850

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.